LAXA
LAXA, licence 80034955: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Distribution Essentiel Moor Inc.
- NPN or DIN-HM
- 80034955
- Status
- Active licence
- Licence date
- 27 August 2012
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Traditionnelle
If this product were sold in France
- Conditions légales
Glycyrrhiza glabra L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Aloe vera (L.) Burm. f.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et une mention déconseillant l'usage prolongé
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Rheum officinale Baill.: L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants de moins de 12 ans, aux femmes enceintes et allaitantes et une mention déconseillant l'usage prolongé.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Glycyrrhiza glabra Source : Racine | 30.0 mg | Not calculated |
| Aloe vera Source : Latex séché de feuille d'aloès | 25.0 mg | Not calculated |
| Rhamnus purshiana Source : Écorce | 150.0 mg | Not calculated |
| Rheum officinale Source : Racine | 8.0 mg | Not calculated |
Non-medicinal ingredients
Gélatine, Stéarate de magnésium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et enfants | minimum: 12.0 Année(s) | 1.0 Capsule | 1.0 Jour(s) |
Uses authorised in Canada
Utilisé traditionnellement en herboristerie comme laxatif stimulant dans les cas de constipation occasionnelle.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Source
Official Health Canada record, licence 80034955
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.